While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), many patients ...
A French prospective real-life cohort confirmed the favorable prognosis of nonmetastatic microsatellite instability (MSI) colorectal cancers. These cancers nevertheless entailed a high risk for ...
Patients with advanced cancer who had ctDNA testing (Guardant360) from October 1, 2018, to June 30, 2022, were retrospectively assessed for prevalence. GuardantINFORM, which includes anonymized ...
Immunotherapy—could that be an option for me, doctor?” is a question frequently asked by patients with colorectal cancer. The ...
A post hoc analysis of the PETACC-8 trial has revealed an interaction between microsatellite instability (MSI) and BRAF and KRAS mutation status when determining the prognosis of patients with ...
Tumors with high levels of microsatellite instability (MSI-H), such as some subsets of colorectal, endometrial and gastric cancers, are associated with a hypermutated phenotype and a specific ...
Nouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback